Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | PRGN-3006 in the treatment of AML and MDS

David Sallman • 11 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes CAR-T PRGN-3006

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses PRGN-3006, a novel chimeric antigen receptor T-cell (CAR-T) therapy, in the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Sallman highlights the mechanism of action of this CAR, its manufacturing process, and concludes by discussing the safety of this product and promising response rates observed in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals